"RefleXion's use of PET emissions to prescriptively determine where to attack the cancer combined with HealthMyne's ability to objectively measure tumor characteristics and quantify treatment response creates a powerful technological foundation from which to improve patient care," said Rose Higgins, CEO at HealthMyne. "In the future, clinicians may have the ability to determine much earlier and with a high degree of accuracy, whether changes to the individual patient's treatment plan are warranted and the predicted outcomes."


About HealthMyne

HealthMyne, a pioneer in applied radiomics, the cutting-edge field of extracting novel data and biomarkers from medical images, believes that every cancer patient's story begins with an image. The company's FDA-approved and CE marked, AI-enabled solutions allow organizations to easily access and translate groundbreaking radiomic insights into use in research, clinical outcomes, and treatment pathways. By leveraging radiomics, HealthMyne's clients and partners can accelerate the development and delivery of the best possible treatments.


About RefleXion
RefleXion is a privately held therapeutic oncology company developing the first biology-guided radiotherapy (BgRT) machine, with the potential to move beyond single tumor therapy to one day treat multiple metastatic tumors throughout the body in the same treatment session. Currently, the RefleXion™ X1 is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.

Back to HCB News

Rad Oncology Homepage